These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 28295923)

  • 1. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
    Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
    J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
    Roberts S; Gordon A; McLean C; Pedersen J; Bowden S; Thomson K; Angus P
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):932-7. PubMed ID: 17544878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    Mandorfer M; Kozbial K; Schwabl P; Freissmuth C; Schwarzer R; Stern R; Chromy D; Stättermayer AF; Reiberger T; Beinhardt S; Sieghart W; Trauner M; Hofer H; Ferlitsch A; Ferenci P; Peck-Radosavljevic M
    J Hepatol; 2016 Oct; 65(4):692-699. PubMed ID: 27242316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
    Mandorfer M; Kozbial K; Freissmuth C; Schwabl P; Stättermayer AF; Reiberger T; Beinhardt S; Schwarzer R; Trauner M; Ferlitsch A; Hofer H; Peck-Radosavljevic M; Ferenci P
    Aliment Pharmacol Ther; 2015 Sep; 42(6):707-18. PubMed ID: 26179884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
    Kotani K; Enomoto M; Uchida-Kobayashi S; Tamori A; Yukawa-Muto Y; Odagiri N; Motoyama H; Kozuka R; Kawamura E; Hagihara A; Fujii H; Kageyama K; Yamamoto A; Yoshida A; Higashiyama S; Kawabe J; Kawada N
    J Gastroenterol; 2023 Apr; 58(4):394-404. PubMed ID: 36729172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.
    Mandorfer M; Kozbial K; Schwabl P; Chromy D; Semmler G; Stättermayer AF; Pinter M; Hernández-Gea V; Fritzer-Szekeres M; Steindl-Munda P; Trauner M; Peck-Radosavljevic M; García-Pagán JC; Ferenci P; Reiberger T
    Hepatology; 2020 Mar; 71(3):1023-1036. PubMed ID: 31365764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
    Rincon D; Ripoll C; Lo Iacono O; Salcedo M; Catalina MV; Alvarez E; Nuñez O; Matilla AM; Clemente G; Bañares R
    Am J Gastroenterol; 2006 Oct; 101(10):2269-74. PubMed ID: 17032192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
    Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
    Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
    Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
    Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
    J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of 833 times measured hepatic venous pressure gradient].
    Zhang MY; Wang GC; Huang GJ; Feng H; Wang LF; Zhang JY; Shi YJ; Zhang CQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):266-270. PubMed ID: 29996337
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.
    Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J
    Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatic cein catheterisation -  selected assessment aspects].
    Petrtýl J; Brůha R; Urbánek P; Mareček Z; Kaláb M
    Vnitr Lek; 2013 Jul; 59(7):587-90. PubMed ID: 23909264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg.
    Jindal A; Bhardwaj A; Kumar G; Sarin SK
    Am J Gastroenterol; 2020 Oct; 115(10):1624-1633. PubMed ID: 32453061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.